Information Provided By: 
Fly News Breaks for March 21, 2016
EGRX
Mar 21, 2016 | 07:22 EDT
William Blair analyst Tim Lugo lowered his price target for Eagle Pharmaceuticals to $88 after the company received a complete response letter from the FDA regarding the new drug application for Kangio, the company's ready-to-use bivalirudin formulation for use as an anticoagulant in several indications. The setback is disappointing and will delay the launch of Kangio. The analyst, however, believes that Bendeka remains the major near term growth driver for Eagle. He keeps an Outperform rating on the shares.
News For EGRX From the Last 2 Days
There are no results for your query EGRX
